Literature DB >> 24566859

Can there be a place for intraoperative salvaged blood in spine tumor surgery?

Naresh Kumar1, Qasim Ahmed, Victor K M Lee, Yongsheng Chen, Aye Sandar Zaw, Raymond Goy, Rohit Vijay Agrawal, Aisha Naheed Dhewar, Hee Kit Wong.   

Abstract

BACKGROUND: Intraoperative cell salvage (IOCS) has been used in musculoskeletal surgery extensively. However, it has never found its place in musculoskeletal oncologic surgery. We have conducted the first-ever study to evaluate the feasibility of IOCS in combination with a leucocyte-depletion filter (LDF) in metastatic spine tumor surgery. This was to pave the path for use of IOCS-LDF in musculoskeletal oncologic surgery.
METHODS: Patients with a known primary epithelial tumor, who were offered surgery for metastatic spinal disease, were recruited. Blood samples were collected at three different stages during the surgery: from the operative field before IOCS processing, after IOCS processing, and after IOCS-LDF processing. Three separate samples (5 mL each) were taken at each stage. Samples were examined using immunohistochemical monoclonal antibodies to identify tumor cells of epithelial origin.
RESULTS: Of 30 patients in the study, 6 were excluded for not fulfilling the inclusion criteria, leaving 24 patients. Malignant tumor cells were detected in the samples from the operative field before IOCS processing in eight patients and in the samples from the transfusion bag after IOCS processing in three patients. No viable malignant cell was detectable in any of the blood samples after passage through both IOCS and LDF.
CONCLUSIONS: The findings support the notion that the IOCS-LDF combination works effectively in eliminating tumor cells from salvaged blood, so this technique can be applied successfully in spine tumor surgery. This concept can then further be extended to whole musculoskeletal tumor surgery and other oncologic surgeries with further appropriate clinical studies.

Entities:  

Mesh:

Year:  2014        PMID: 24566859     DOI: 10.1245/s10434-014-3569-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

Review 1.  Clinical Utility of Autologous Salvaged Blood: a Review.

Authors:  Steven M Frank; Robert A Sikorski; Gerhardt Konig; Diamantis I Tsilimigras; Jan Hartmann; Mark A Popovsky; Timothy M Pawlik; Jonathan H Waters
Journal:  J Gastrointest Surg       Date:  2019-08-29       Impact factor: 3.452

2.  Effectiveness of intraoperative cell salvage combined with a modified leucocyte depletion filter in metastatic spine tumour surgery.

Authors:  Ya-Nan Zong; Chuan-Ya Xu; Yue-Qing Gong; Xiao-Qing Zhang; Hong Zeng; Chang Liu; Bin Zhang; Li-Xiang Xue; Xiang-Yang Guo; Feng Wei; Yi Li
Journal:  BMC Anesthesiol       Date:  2022-07-12       Impact factor: 2.376

3.  Intraoperative cell salvage in metastatic spine tumour surgery reduces potential for reinfusion of viable cancer cells.

Authors:  Naresh Kumar; Aye Sandar Zaw; Bee Luan Khoo; Sayantani Nandi; Zhangxing Lai; Gurpal Singh; Chwee Teck Lim; Jean Paul Thiery
Journal:  Eur Spine J       Date:  2016-03-07       Impact factor: 3.134

4.  Current Status of the Use of Salvaged Blood in Metastatic Spine Tumour Surgery.

Authors:  Naresh Kumar; Nivetha Ravikumar; Joel Yong Hao Tan; Kutbuddin Akbary; Ravish Shammi Patel; Rajesh Kannan
Journal:  Neurospine       Date:  2018-08-03

5.  Survival analysis of intraoperative blood salvage for patients with malignancy disease: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Wei-Wei Wu; Wei-Yi Zhang; Wei-Han Zhang; Lei Yang; Xiao-Qian Deng; Meng-Chan Ou; Yao-Xin Yang; Hai-Bei Liu; Tao Zhu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study.

Authors:  Andreas Winter; Kai Zacharowski; Patrick Meybohm; Andreas Schnitzbauer; Peter Ruf; Claudia Kellermann; Horst Lindhofer
Journal:  BMC Anesthesiol       Date:  2021-10-29       Impact factor: 2.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.